

Literatura ACTA MEDICINAE 3/2025 Biologická a cílená léčba

- 3 **Inhibitory imunitních kontrolních bodů v léčbě skvamózních karcinomů hlavy a krku**
doc. MUDr. Milan Vošmik, Ph.D. | MUDr. Libor Hruška | MUDr. Miroslav Hodek, Ph.D. Klinika onkologie a radioterapie, Lékařská fakulta UK a Fakultní nemocnice Hradec Králové
- 3 **HER2-low karcinom prsu – vhodný cíl pro novou léčbu**
prof. MUDr. Petra Tesařová, CSc. Ústav radiační onkologie, 1. LF UK a FN Bulovka, Praha; IPVZ Praha; Onkologická klinika, 1. LF UK a VFN v Praze
- 3 **Léčba karcinomu ledviny na začátku roku 2025**
MUDr. David Feldmar | prof. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika, 2. LF UK a Fakultní nemocnice v Motole, Praha
- 4 **Cílená léčba karcinomu žaludku – aktuální přehled léčebných možností**
MUDr. Tomáš Sokop | doc. MUDr. Radka Lordick Obermannová, Ph.D. Klinika komplexní onkologické péče Masarykova onkologického ústavu a Lékařské fakulty Masarykovy univerzity, Brno
- 4 **Využití inhibitorů PARP v léčbě karcinomu prostaty se zaměřením na studii PROPEL, včetně klinické zkušenosti**
MUDr. Darja Šustrová Onkologická klinika, 2. LF UK a FN v Motole, Praha
- 5 **Léčebné možnosti lokálně pokročilého nemalobuněčného karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika, 2. LF UK a FN v Motole, Praha
- 5 **Pacientka s metastatickým nádorem prsu a mutací *RAD51C* a léčba sacituzumab govitecanem – kazuistika**
MUDr. Dagmar Brančíková, Ph.D. Interní hematologická a onkologická klinika, FN Brno a LF MU, Brno
- 5 **Využití CAR-T lymfocytů v léčbě nehodgkinských lymfomů**
MUDr. Tereza Shokralla | MUDr. Kamila Polgárová, Ph.D. I. interní klinika – klinika hematologie, VFN v Praze a 1. LF UK, Praha
- 6 **Monoklonální protilátky – daratumumab, isatuximab, elotuzumab – v léčbě mnohočetného myelomu. Můžeme už myelom vyléčit?**
prof. MUDr. Ivan Špička, CSc. I. interní klinika, klinika hematooonkologie, LF UK a VFN, Praha
- 6 **Biologická léčba systémové AL amyloidózy**
MUDr. Tomáš Pika, Ph.D. Hematoonkologická klinika, LF UP a FN Olomouc
- 7 **Biologická léčba astmatu – současné možnosti**
MUDr. Eva Voláková, Ph.D. Klinika plicních nemocí a tuberkulózy, FN Olomouc a LF UP v Olomouci
- 7 **Novinky v léčbě autozomálně dominantních polycystických ledvin**
doc. MUDr. Jana Reiterová, Ph.D. Klinika nefrologie, 1. LF UK a VFN, Praha
- 7 **Monoklonální protilátky v léčbě Alzheimerovy choroby**
MUDr. Mgr. Adam Tesař, Ph.D. Neurologická klinika, 1. LF UK a VFN, Praha
- 8 **Lupusová nefritida – co nám přinášejí nová doporučení?**
MUDr. Ester Kurašová | prof. MUDr. Karel Krejčí, Ph.D. | prof. MUDr. Pavel Horák, CSc. Univerzita Palackého v Olomouci, Lékařská fakulta a Fakultní nemocnice Olomouc, III. interní klinika – nefrologická, revmatologická a endokrinologická
- 8 **Biosimilární léčiva v dermatologii u pacientů s diagnózou psoriasis vulgaris, efektivita a cenové přínosy – kazuistika**
MUDr. et Bc. Lucie Jarešová DermaMedEst, s. r. o.
- 8 **Behçetova nemoc**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
prof. MUDr. Jarmila Heissigerová, Ph.D., MBA Oční klinika, 1. LF UK a VFN, Praha
- 9 **Mirikizumab v terapii Crohnovy choroby**
doc. MUDr. Martin Bortlík, Ph.D. Gastroenterologické oddělení, Nemocnice České Budějovice, a. s.; Interní klinika, 1. LF UK a ÚVN, Praha; Farmakologický ústav, 1. LF UK, Praha; Zdravotně sociální fakulta Jihočeské univerzity, České Budějovice
- 9 **Stillova choroba dospělých – kazuistika**
MUDr. Ondřej Sglunda Poliklinika Modrý pavilon, Slezská Ostrava

9 Psoriáza – přehled o terapii; indikace k biologické léčbě

doc. MUDr. Jarmila Čelakovská, Ph.D. Klinika nemocí kožních a pohlavních, FN a LF UK v Hradci Králové

9 Psoriáza a obezita: co bychom měli vědět? Kazuistika pacientky s těžkou formou psoriázy a obezitou, úspěšně léčené ixekizumabem

MUDr. Michaela Nováková Dermatovenerologická klinika, FN Bulovka a 2. LF UK; Dermatovenerologická ambulance, IKEM, Praha

Inhibitory imunitních kontrolních bodů v léčbě skvamózních karcinomů hlavy a krku

doc. MUDr. Milan Vošmik, Ph.D. | MUDr. Libor Hruška | MUDr. Miroslav Hodek, Ph.D. Klinika onkologie a radioterapie, Lékařská fakulta UK a Fakultní nemocnice Hradec Králové

- 1 Wolchok, J. D. – Chiarion-Sileni, V. – Rutkowski, P., et al.; CheckMate 067 investigators: final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med*, 2025, 392, s. 11–22.
- 2 Postow, M. A.: Managing immune check point-blocking antibody side effects. *Am Soc Clin Oncol Educ Book*, 2015, s. 76–83.
- 3 Eggermont, A. M. – Kicinski, M. – Blank, C. U., et al.: Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC 1325 / KEYNOTE-054 trial. *Eur J Cancer*, 2024, 211, 114327.
- 4 Weber, J. S. – Middleton, M. R. – Yates, G., et al.: Estimating long-term survivorship rates among patients with resected stage III/IV melanoma: analyses from CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 trials. *J Clin Oncol*, 2024, JCO2400237.
- 5 Spigel, D. R. – Faivre-Finn, C. – Gray, J. E., et al.: Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *J Clin Oncol*, 2022, 40, s. 1301–1311.
- 6 Choueiri, T. K. – Tomczak, P. – Park, S. H., et al.; KEYNOTE-564 investigators: Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. *N Engl J Med*, 2024, 390, s. 1359–1371.
- 7 Kelly, R. J. – Ajani, J. A. – Kuzdzal, J., et al.; CheckMate 577 investigators: Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med*, 2021, 384, s. 1191–1203.
- 8 Shi, H. – Zhang, W. – Zhang, L., et al.: Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis. *Front Immunol*, 2023, 14, 1265202.
- 9 Forastiere, A. A. – Metch, B. – Schuller, D. E., et al.: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. *J Clin Oncol*, 1992, 10, s. 1245–1251.
- 10 Jacobs, C. – Lyman, G. – Velez-García, E., et al.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol*, 1992, 10, s. 257–263.
- 11 Vermorken, J. B. – Mesia, R. – Rivera, F., et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med*, 2008, 359, s. 1116–1127.
- 12 Ferris, R. L. – Blumenschein, G. Jr. – Fayette, J., et al.: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *N Engl J Med*, 2016, 375, s. 1856–1867.
- 13 Ferris, R. L. – Blumenschein, G. Jr. – Fayette, J., et al.: Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. *Oral Oncol*, 2018, 81, s. 45–51.
- 14 Harrington, K. J. – Ferris, R. L. – Blumenschein, G., Jr., et al.: Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 1104–1115.
- 15 Cohen, E. E. W. – Soulières, D. – Le Tourneau, C., et al.; KEYNOTE-040 investigators: Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *Lancet*, 2019, 393, s. 156–167.
- 16 Burtneš, B. – Harrington, K. J. – Greil, R., et al.: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet*, 2019, 394, s. 1915–1928.
- 17 Harrington, K. J. – Burtneš, B. – Greil, R., et al.: Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. *J Clin Oncol*, 2023, 41, s. 790–802.
- 18 Rischin, D. – Harrington, K. J. – Greil, R., et al.: Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. *Oral Oncol*, 2022, 128, 105815.
- 19 Lee, N. Y. – Ferris, R. L. – Psyrri, A., et al.: Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 450–462.
- 20 Machiels, J. P. – Tao, Y. – Licitra, L., et al.; KEYNOTE-412 investigators: Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. *Lancet Oncol*, 2024, 25, s. 572–587.
- 21 Tao, Y. – Aupeirin, A. – Sun, X., et al.: 854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial. *Ann Oncol*, 2024, 36, suppl. 2, s. S616.
- 22 Merck's KEYTRUDA (pembrolizumab) met primary endpoint of event-free survival (EFS) as perioperative treatment regimen in patients with resected, locally advanced head and neck squamous cell carcinoma. News release, Merck, 8. 10. 2024. Dostupné z: <https://www.businesswire.com/news/home/20241008593341/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Met-Primary-Endpoint-of-Event-Free-Survival-EFS-as-Perioperative-Treatment-Regimen-in-Patients-With-Resected-Locally-Advanced-Head-and-Neck-Squamous-Cell-Carcinoma>, vyhledáno 19. 1. 2025.
- 23 GORTEC announces new trial success for head and neck cancer treatment. GORTEC, 8. 1. 2025. Dostupné z: <https://www.prnewswire.com/news-releases/gortec-announces-new-trial-success-for-head-and-neck-cancer-treatment-302344111.html>, vyhledáno 19. 1. 2025.

HER2-low karcinom prsu – vhodný cíl pro novou léčbu

prof. MUDr. Petra Tesařová, CSc. Ústav radiační onkologie, 1. LF UK a FN Bulovka, Praha; IPVZ Praha;

Onkologická klinika, 1. LF UK a VFN v Praze

- 1 Tarantino, P. – Viale, G. – Press, M. F., et al.: ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. *Ann Oncol*, 2023, 34, s. 645–659.
- 2 Corti, C. – Giugliano, F. – Nicolò, E., et al.: HER2-low breast cancer: a new subtype? *Curr Treat Options Oncol*, 2023, 24, s. 468–478.
- 3 Nicolò, E. – Tarantino, P. – Curigliano, G.: Biology and treatment of HER2-low breast cancer. *Hematol Oncol Clin North Am*, 2023, 37, s. 117–132.
- 4 Li, Y. – Tsang, J. – Tam, F., et al.: Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment. *eBioMedicine*, 2023, 91, 104571.
- 5 Molinelli, C. – Jacobs, F. – Agostinotto, E., et al.: Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis. *ESMO Open*, 2023, 8, 101592.
- 6 Modi, S.: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study. *Future Oncol*, 2025, 21, s. 367–380.
- 7 Bardia, A. – Hurvitz, S. A. – Tolaney, S. M., et al.; ASCENT Clinical Trial Investigators: Sacituzumab govitecan in metastatic triple-negative breast cancer. *N Engl J Med*, 2021, 384, s. 1529–1541.
- 8 Rugo, H. S. – Bardia, A. – Marmé, F., et al.: Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPIC5-02): a randomised, open-label, multicentre, phase 3 trial. *Lancet*, 2023, 402, s. 1423–1433.
- 9 Bardia, A. – Hu, X. – Dent, R., et al.; DESTINY-Breast06 Trial Investigators: Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. *N Engl J Med*, 2024, 391, s. 2110–2122.
- 10 Tarantino, P. – Hughes, M. – Kusmick, R., et al.: Abstract P508-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE). *Cancer Res*, 2024, 84.
- 11 Abelman, R. O. – Spring, L. – Fell, G., et al.: Abstract P508-03: Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis. *Cancer Res*, 2024, 84.
- 12 Jhaveri, K. – Hamilton, E. – Loi, S., et al.: Abstract OT-03-05: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08). *Cancer Res*, 2021, 81.
- 13 Wang, Y. – Liu, Y. – Zhang, Q., et al.: RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. *J Clin Oncol*, 2021, 39.
- 14 Davis, A. A. – Dumbava, E. E. – Kalyan, A., et al.: Abstract CT159: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495). *Cancer Res*, 2024, 84.
- 15 Andre, F. – Hamilton, E. P. – Loi, S., et al.: Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC). *J Clin Oncol*, 2022, 40.
- 16 Hamilton, E. – Shapiro, C. L. – Petrylak, D., et al.: Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study. *Cancer Res*, 2021, 81.
- 17 Schmid, P. – Im, S. A. – Armstrong, A., et al.: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC) – Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). *J Clin Oncol*, 2021, 39.
- 18 Borghaei, H. – Besse, B. – Bardia, A., et al.: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NS-CLC): A phase 1b, multicenter, study. *J Clin Oncol*, 2020, 38.
- 19 Wang, Y. – Liu, Y. – Zhang, Q., et al.: RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. *J Clin Oncol*, 2021, 39.
- 20 Banerji, U. – van Herpen, C. M. L. – Saura, C., et al.: Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. *Lancet Oncol*, 2019, 20, s. 1124–1135.
- 21 Hu, X. – Zhang, J. – Liu, R., et al.: Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. *J Clin Oncol*, 2021, 39.

Léčba karcinomu ledviny na začátku roku 2025

MUDr. David Feldmar | prof. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika, 2. LF UK a Fakultní nemocnice v Motole, Praha

- 1 Choueiri, T. K. – Tomczak, P. – Park, S. H., et al.: Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. *N Engl J Med*, 2021, 385, s. 683–694.
- 2 Motzer, R. J. – Tannir, N. M. – McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med*, 2019, 380, s. 1103–1115.
- 3 Motzer, R. J. – Penkov, K. – Hagan, J., et al.: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*, 2019, 380, s. 1103–1115.
- 4 Motzer, R. J. – Powles, T. – Burotto, M., et al.: Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from

an open-label, randomised, phase 3 trial. *Lancet Oncol*, 2022, 23, s. 888–898.

5 **Motzer, R. J. – Porta, C. – Eto, M., et al.**: Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus

pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). *J Clin Oncol*, 2023, 41, suppl. 16, 4502.

Cílená léčba karcinomu žaludku – aktuální přehled léčebných možností

MUDr. Tomáš Sokop | doc. MUDr. Radka Lordick Obermannová, Ph.D. Klinika komplexní onkologické péče Masarykova onkologického ústavu a Lékařské fakulty Masarykovy univerzity, Brno

- 1 **Kiss, I., et al.**: *Modrá kniha České onkologické společnosti*. 30. aktualizace. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>, vyhledáno 27. 11. 2024.
- 2 **Lordick, F., et al.**: Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2022, 33, s. 1005–1020.
- 3 **Lordick, F. – Candia Montero, L. – Castelo-Branco, G., et al.**: ESMO Gastric Cancer Living Guideline, v. 1.4 September 2024, 1.4. Dostupné z: <https://www.esmo.org/living-guidelines/esmo-gastric-cancer-living-guideline>, vyhledáno 27. 11. 2024.
- 4 **Bose, C. K. – Mukhopadhyay, S.**: Combined positive score (CPS) for scoring PD-L1 positivity. *Cancer Research, Statistics, and Treatment*, 2022, 5, s. 765–766.
- 5 **Corallo, S., et al.**: Unlocking the potential: Epstein-Barr Virus (EBV) in gastric cancer and future treatment prospects, a literature review. *Pathogens*, 2024, 13, s. 728.
- 6 **Salnikov, M. Y. – MacNeil, K. M. – Mymryk, J. S.**: The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape. *Front Immunol*, 2024, 15, s. 1358511.
- 7 **Lordick, F. – Rha, S. Y. – Muro, K., et al.**: Systemic therapy of gastric cancer – state of the art and future perspectives. *Cancers*, 2024, 16, s. 3337.
- 8 **Mosele, M. F., et al.**: Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*, 2024, 35, s. 588–606.
- 9 **André, T., et al.**: Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONPIGA phase II study. *J Clin Oncol*, 2023, 41, s. 255–265.
- 10 **Pietrantonio, F., et al.**: INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). *J Clin Oncol*, 2023, 41, s. 358–358.
- 11 **Lorenzen, S., et al.**: Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase III/III DANTE/IKF-s633 trial. *J Clin Oncol*, 2024, 42, s. 410–420.
- 12 **Hofheinz, R., et al.**: Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. *Int J Cancer*, 2021, 149, s. 1322–1331.
- 13 **Al-Batran, S.-E., et al.**: 1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma. *Ann Oncol*, 2020, 31, s. S899.
- 14 **Scheck, M. K. – Hofheinz, R. D. – Lorenzen, S.**: HER2-positive gastric cancer and antibody treatment: state of the art and future developments. *Cancers*, 2024, 16, s. 1336.
- 15 **Wagner, A. D., et al.**: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group. *J Clin Oncol*, 2023, 41, suppl. 16, s. 4057–4057.
- 16 **Bang, Y.-J., et al.**: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*, 2010, 376, s. 687–697.
- 17 **Shitara, K., et al.**: Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. *N Engl J Med*, 2020, 382, s. 2419–2430.
- 18 **Van Cutsem, E., et al.**: Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. *Lancet Oncol*, 2023, 24, s. 744–756.
- 19 **Shitara, K., et al.**: Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. *Nat Med*, 2024, 30, s. 1933–1942.
- 20 **Rha, S. Y., et al.**: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol*, 2023, 24, s. 1181–1195.
- 21 **Janjigian, Y. Y., et al.**: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. *Lancet*, 2023, 402, s. 2197–2208.
- 22 **Muro, K., et al.**: 1513MO A phase II study of nivolumab plus low dose ipilimumab as first-line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIM-IT study (WJOG13320G/CA209-7W7). *Ann Oncol*, 2023, 34, suppl. s. S852–S853.
- 23 **Chao, J., et al.**: Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. *JAMA Oncol*, 2021, 7, s. 895–902.
- 24 **Yoon, H. H., et al.**: Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. *JAMA Oncol*, 2022, 8, s. 1456–1465.
- 25 **Maio, M., et al.**: Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. *Ann Oncol*, 2022, 33, s. 929–938.
- 26 **Nakayama, I. – Qi, Ch. – Chen, Y., et al.**: Claudin 18.2 as a novel therapeutic target. *Nat Rev Clin Oncol*, 2024, 21, s. 354–369.
- 27 **Shitara, K., et al.**: Zolbetuximab plus mFOLFFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet*, 2023, 401, s. 1655–1668.
- 28 **Gordon, A. – Johnston, E. – Lau, D. K., et al.**: Targeting FGFR2 positive gastroesophageal cancer: current and clinical developments. *Oncology Targets Ther*, 2022, 15, s. 1183–1196.
- 29 **Smyth, E. C., et al.**: Trial in progress: Phase 3 study of bemarituzumab + mFOLFFOX6 versus placebo + mFOLFFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101). *J Clin Oncol*, 2022, 40, suppl. 16, s. TPS4164–TPS4164.
- 30 **Balmaceda, N. B., et al.**: State-of-the-art advancements in gastroesophageal cancer treatment: harnessing biomarkers for precision care. *Am Soc Clin Oncol Educ Book*, doi: https://doi.org/10.1200/EDBK_431060.
- 31 **Janjigian, Y. Y., et al.**: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*, 2021, 398, s. 27–40.
- 32 **Wilke, H., et al.**: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1224–1235.

Využití inhibitorů PARP v léčbě karcinomu prostaty se zaměřením na studii PROPEL, včetně klinické zkušenosti

MUDr. Darja Šustrová Onkologická klinika, 2. LF UK a FN v Motole, Praha

- 1 **Mateo, J. – McKay, R. – Abida, W., et al.**: Accelerating precision medicine in metastatic prostate cancer. *Nat Cancer*, 2020, 1, s. 1041–1053.
- 2 **PoDianov, G. L.**: Base excision repair targets for cancer therapy. *Am J Cancer Res*, 2011, 1, s. 845–851.
- 3 **Mao, Z. – Bozzella, M. – Seluanov, A., et al.**: Comparison of non-homologous end joining and homologous recombination in human cells. *DNA Repair*, 2008, 7, s. 1765–1771.
- 4 **Zhao, B. – Rothenberg, E. – Ramsden, D. A., et al.**: The molecular basis and disease relevance of non-homologous DNA end joining. *Nat Rev Mol Cell Biol*, 2020, 21, s. 765–781.
- 5 **Roy, R. – Chun, J. – Powell, S. N.**: BRCA1 and BRCA2: Different roles in a common pathway of genome protection. *Nat Rev Cancer*, 2011, 12, s. 68–78.
- 6 **Shui, I. M. – Burcu, M. – Shao, C., et al.**: Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. *Prostate Cancer Prostatic Dis*, 2024, 27, s. 728–735.
- 7 **Li, X. – Heyer, W.-D.**: Homologous recombination in DNA repair and DNA damage tolerance. *Cell Res*, 2008, 18, s. 99–113.
- 8 **Roy, R. – Chun, J. – Powell, S.**: BRCA1 and BRCA2: different roles in a common pathway of genome protection. *Nat Rev Cancer*, 2012, 12, s. 68–78.
- 9 **Yap, T. A. – Sandhu, S. K. – Carden, C. P., et al.**: Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. *CA Cancer J Clin*, 2011, 61, s. 31–49.
- 10 **Shore, N. D. – Vasudevan, A. – Li, J., et al.**: Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration resistant prostate cancer (mCRPC). *J Clin Oncol*, 2025, 43, suppl. 5, s. 85.
- 11 **Olmos, D. – Lorente, D. – Alameda, C., et al.**: Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. *Ann Oncol*, 2024, 35, s. 458–472.
- 12 **De Bono, J. S., et al.**: First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. *J Clin Oncol*, 2019, 37, s. 3007.
- 13 **Rafei, S. – Fitzpatrick, K. – Liu, D., et al.**: ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. *Cancer Res*, 2020, 80, s. 2094–2100.
- 14 **Valsecchi, A. A. – Dionisio, R. – Panepinto, O., et al.**: Frequency of germline and somatic BRCA1 and BRCA2 mutations in prostate cancer: an updated systematic review and meta-analysis. *Cancers*, 2023, 15, s. 2435.
- 15 **Pritchard, C. C. – Mateo, J. – Walsh, M. F., et al.**: Inherited DNA-repair gene mutations in men with metastatic prostate cancer. *N Engl J Med*, 2016, 375, s. 443–453.
- 16 **Castro, E. – Romero-Laorden, N. – Del Pozo, A., et al.**: PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. *J Clin Oncol*, 2019, 37, s. 490–503.
- 17 **Robinson, D. – Van Allen, E. M. – Wu, Y. M., et al.**: Integrative clinical genomics of advanced prostate cancer. *Cell*, 2015, 161, s. 1215–1228.
- 18 **Sciarra, A. – Fiori, C. – Del Giudice, F., et al.**: DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: Achieved answers, open questions and future perspectives. *Minerva Urol Nephrol*, 2022, 74, s. 649–652.
- 19 **Lilly, E. – Sarkis, J. – Mahmoud, O., et al.**: Novel breakthroughs in advanced prostate cancer management. *Expert Rev Anticancer Ther*, 2023, 23, s. 369–373.
- 20 **Fizazi, K. – Piułats, J. M. – Reaume, M. N., et al.**: Rucaparib or physician's choice in metastatic prostate cancer. *N Engl J Med*, 2023, 388, s. 719–732.
- 21 **Hung, A. – Candelieri, D. – Li, Y., et al.**: Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer. *Semin Oncol*, 2023, 50, s. 11–24.
- 22 **Rajwa, P. – Quhal, F. – Praderer, B., et al.**: Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. *Nat Rev Urol*, 2023, 20, s. 205–216.
- 23 **Schweizer, M. T. – Sivakumar, S. – Tukachinsky, H., et al.**: Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA. *JAMA Oncol*, 2021, 7, s. 1–5.
- 24 **Leith, J. A. – Ribbans, A. – Last, M., et al.**: Genomic/genetic testing patterns for patients with metastatic castrate-resistant prostate cancer: results from a real-world study in the United States. *J Clin Oncol*, 2019, 37, suppl. 6, s. 49–49.
- 25 **Clarke, N. W. – Armstrong, A. J. – Thiery-Vuillemin, A., et al.**

- Abiraterone and olaparib for metastatic castration-resistant prostate cancer. *NEJM Evid*, 2022, 1, doi:10.1056/EVIDoa2200043.
- 26 Carr, T. H. – Adelman, C. – Barnicle, A., et al.: Homologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castration-resistant prostate cancer. *Cancers*, 2021, 13, s. 5830.
 - 27 Saad, F. – Thiery-Vuillemin, A. – Wiechno, P., et al.: Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: A randomised, double-blind, phase 2 trial. *Lancet Oncol*, 2022, 23, s. 1297–1307.
 - 28 Clarke, N. W. – Armstrong, A. J. – Thiery-Vuillemin, A., et al.: Final overall survival (OS) in PROPEL: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*, 2023, 41, suppl. 6, LBA16.
 - 29 Saad, F., et al.: 1357O Biomarker analysis and updated results from the Phase III PROPEL trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *Ann Oncol*, 2022, 33, S1160.
 - 30 Fallah, J. – Xu, J. – Weinstock, C. – Brave, M. H., et al.: FDA approval summary: Olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer. *J Clin Oncol*, 2024, 42, s. 605–613.
 - 31 Clarke, N.: Final overall survival in PROPEL: abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer. ASCO GU 2023; dostupné z: <https://meetings.asco.org/abstracts-presentations/217650>, vyhledáno 17. 3. 2025.
 - 32 Saad, F. – Armstrong, A. J. – Thiery-Vuillemin, A., et al.: MP11-16 Prostate-specific antigen analyses in PROPEL: abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer. *J Urol*, 2023, 209, suppl. 4, s. e131.
 - 33 Saad, F. – Clarke, N. W. – Oya, M., et al.: Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROPEL): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. *Lancet Oncol*, 2023, 24, s. 1094–1108.
 - 34 Saad, F. – Armstrong, A. J. – Oya, M., et al.: Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the phase 3 PROPEL trial. *Eur Urol Oncol*, 2024, 7, s. 1394–1402.
 - 35 Saad, F. – Armstrong, A. – Oya, M., et al.: Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROPEL trial. *J Clin Oncol*, 2025, 43, suppl. 5, s. 219.
 - 36 Messina, C. – Giunta, E. F. – Signori, A., et al.: Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis. *Eur Urol Oncol*, 2024, 7, s. 179–188.
 - 37 Naqvi, S. A. A. – Riaz, I. B. – Bibi, A., et al.: Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis. *Europ Urol*, 2025, doi.org/10.1016/j.eururo.2024.12.007.
 - 38 Akay, M. – Funingana, I.-G. – Patel, G., et al.: An in-depth review of niraparib in ovarian cancer: mechanism of action, clinical efficacy and future directions. *Oncol Ther*, 2021, 9, s. 347–364.
 - 39 Olmos, D. – Lorente, D. – Alameda, D., et al.: Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. *Ann Oncol*, 2024, 35, s. 458–472.
 - 40 Oya, M. – Armstrong, A. J. – Thiery-Vuillemin, A., et al.: 1570 Biomarker analysis and updated results from the phase III PROPEL trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *Ann Oncol*, 2023, 34, s. S975–S976.
 - 41 Mehra, N. – Clarke, N. W. – Armstrong, A. J., et al.: 1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAM) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PROPEL trial. *Ann Oncol*, 2023, 34, s. S975–S976.
 - 42 Clarke, N. W. – Armstrong, A. J. – Thiery-Vuillemin, A., et al.: Final overall survival (OS) in PROPEL: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*, 2023, 41, suppl. 6.
 - 43 Shore, N. D. – Clarke, N. – Armstrong, A. J., et al.: Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRM) in the PROPEL trial. *J Clin Oncol*, 2024, 42, suppl. 4.

Léčebné možnosti lokálně pokročilého nemalobuněčného karcinomu plic

MUDr. Leona Kubková | Pneumologická klinika, 2. LF UK a FN v Motole, Praha

- 1 Spigel, D. – Faivre-Finn, C. – Gray, J. E., et al.: Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. *J Clin Oncol*, 2022, 40, s. 1301–1311.
- 2 Lu, S. – Kato, T. – Dong, X., et al.: Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. *N Engl J Med*, 2. 6. 2024, online.
- 3 Lu, S. – Kato, T. – Dong, X., et al.: Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. *N Engl J Med*, 2024, 391, s. 585–597.
- 4 Kilickap, S. – Sezer, A. – Özgüroğlu, M., et al.: OA11.06 cemiplimab monotherapy for first line advanced NSCLC patients with PD-L1 expression $\geq 50\%$: 5-y outcomes of EMPOWER-Lung 1. *J Thorac Oncol*, 2024, 19, s. 535.
- 5 Makharadze, T. – Gogishvili, M. – Melkadze, T., et al.: Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 Part 2 trial. *J Thorac Oncol*, 2023, 18, s. 755–768.
- 6 Baramidze, A. – Makharadze, T. – Gogishvili, M., et al.: Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 $\geq 1\%$: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. *Lung Cancer*, 2024, 193, 107821.

Pacientka s metastatickým nádorem prsu a mutací RAD51C a léčba sacituzumab govitecanem – kazuistika

MUDr. Dagmar Brancíková, Ph.D. | Interní hematologická a onkologická klinika, FN Brno a LF MU, Brno

- 1 Bardia, A. – Mayer, I. A. – Diamond, J. R., et al.: Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. *J Clin Oncol*, 2017, 35, s. 2141–2148.
- 2 Cardillo, T. M. – Rossi, D. I. – Zalath, M. B., et al.: Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. *Oncotarget*, 2020, 11, s. 29629–29644.
- 3 Li, N. – McInerney, S. – Zethoven, M., et al.: Combined tumor sequencing and case-control analyses of RAD51C in breast cancer. *J Natl Cancer Inst*, 2019, 111, s. 1332–1338.
- 4 Min, A. – Im, S. A. – Yoon, Y.-K., et al.: RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. *Mol Cancer Ther*, 2013, 12, s. 865–877.
- 5 Rugo, H. S. – Bardia, A. – Tolaney, S. M., et al.: TROPICS-02: A phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. *Future Oncol*, 2020, 16, s. 705–715.

Využití CAR-T lymfocytů v léčbě ne Hodgkinových lymfomů

MUDr. Tereza Shokralla | MUDr. Kamila Polgárová, Ph.D. | Interní klinika – klinika hematologie, VFN v Praze a 1. LF UK, Praha

- 1 Lu, J. – Jiang, G.: The journey of CAR-T therapy in hematological malignancies. *Mol Cancer*, 2022, 21, s. 194.
- 2 Subklewe, M. – von Bergwelt-Baildon, M. – Humpe, A.: Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. *Transfus Med Hemother*, 2019, 46, s. 15–24.
- 3 Dejenie, T. A. – G/Medhin, M. T. – Terefe, G. D., et al.: Current updates on generations, approvals, and clinical trials of CAR-T cell therapy. *Hum Vaccin Immunother*, 2022, 18, 2114254.
- 4 Montalvo, M. J. – Bandey, I. N. – Rezvan, A., et al.: Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. *Cell Death Dis*, 2024, 15, s. 109.
- 5 Tao, Z. – Chyra, Z. – Kotulová, J., et al.: Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. *Blood Cancer J*, 2024, 14, s. 213.
- 6 Kong, Y. – Li, J. – Zhao, X., et al.: CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. *Frontiers in Immunology*, 2025, dostupné z: <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1519671>, vyhledáno 8. 2. 2025.
- 7 Iacoboni, G., et al.: CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas: Present and Future. ASH Annual Meeting and Exposition. Abstract 763. 10–13. 12. 2022, New Orleans. Dostupné z: <https://ascopost.com/issues/february-10-2020/car-t-cell-gene-therapy-in-non-hodgkin-lymphomas-present-and-future/>, vyhledáno 19. 2. 2025.
- 8 Zhoubné novotvary lymfatických tkání (C81–86). Linkos CZ, 2025. Dostupné z: <https://www.linkos.cz/files/modra-kniha/23/917.pdf>, vyhledáno 19. 2. 2025.
- 9 Bhaskar, S. T. – Dholaria, B. – Savani, B. N., et al.: The evolving role of bridging therapy during CAR-T therapy. *Clin Hematol Int*, 2024, 6, s. 9–16.
- 10 Patel, S. – Cenin, D. – Corrigan, D., et al.: Siltuximab for first-line treatment of cytokine release syndrome: a response to the national shortage of tocilizumab. *Blood*, 2022, 140, suppl. 1, s. 5073–5074.
- 11 Genoud, V. – Migliorini, D.: Novel pathophysiological insights into CAR-T cell associated neurotoxicity. *Front Neural*, 2023, 14, 1108297.
- 12 Chohan, K. L. – Siegler, E. L. – Kenderian, S. S.: CAR-T cell therapy: the efficacy and toxicity balance. *Curr Hematol Malig Rep*, 2023, 18, s. 9–18.
- 13 Jain, T. – Olson, T. S. – Locke, F. L.: How I treat cytopenias after CAR T-cell therapy. *Blood*, 2023, 141, s. 2460–2469.
- 14 Verdun, N. – Marks, P.: Secondary cancers after chimeric antigen receptor T-cell therapy. *N Engl J Med*, 2024, 390, s. 584–586.
- 15 Hamilton, M. P. – Sugio, T. – Noordenbos, T., et al.: Risk of second tumors and T-cell lymphoma after CAR-T cell therapy. *N Engl J Med*, 2024, 390, s. 2047–2060.
- 16 Neelapu, S. S. – Jacobson, C. A. – Ghobadi, A., et al.: Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. *Blood*, 2023, 141, s. 2307–2315.
- 17 Abramson, J. S. – Palomba, M. L. – Gordon, L. I., et al.: Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. *Blood*, 2024, 143, s. 404–416.
- 18 Morschhauser, F. – Dahiya, S. – Palomba, M. L., et al.: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. *Nat Med*, 2024, 30, s. 2199–2207.
- 19 Fowler, N. H. – Dickinson, M. – Dreyling, M., et al.: Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*, 2022, 28, s. 325–332.
- 20 Wang, M. – Munoz, J. L. – Goy, A. G., et al.: Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. *J Clin Oncol*, 2023, 41, s. 555–567.
- 21 Kordbacheh, T. – Prica, A. – Chan, K. W., et al.: A real-world comparison of CAR T-cell therapy versus a historical standard-of-care approach for relapsed-refractory large B-cell lymphoma in Ontario, Canada. *Blood*, 2024, 144, suppl. 1, s. 5134.
- 22 Bethge, W. A. – Martus, P. – Schmitt, M., et al.: GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. *Blood*, 2022, 140, s. 349–358.
- 23 Kwon, M. – Iacoboni, G. – Reguera, J. L., et al.: Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. *Haematologica*, 2023, 108, s. 110–121.
- 24 Bachy, E. – Le Guillou, S. – Di Blasi, R., et al.: A real-world comparison

- of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. *Nat Med*, 2022, 28, s. 2145–2154.
- 25 Westin, J. R. – Oluwole, O. O. – Kersten, M. J., et al.: Survival with axicabtagene ciloleucel in large B-cell lymphoma. *N Engl J Med*, 2023, 389, s. 148–157.
- 26 Kamdar, M. K. – Solomon, S. R. – Arnason, J., et al.: Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. *J Clin Oncol*, 2024, 42, suppl. 16, s. 7013.
- 27 Bishop, M. R. – Dickinson, M. – Purtil, D., et al.: Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 629–639.
- 28 Chavez, J. C. – Dickinson, M. – Munoz, J. L., et al.: 3-year analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). *Blood*, 2023, 142, suppl. 1, s. 894.
- 29 Westin, J. – Jacobson, C. A. – Chavez, J. C., et al.: ZUMA-23: A global, phase 3, randomizes controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma. *Hematol Oncol*, 2023, 41, s. 171–173.
- 30 Vose, J. M. – Cheah, C. Y. – Clausen, M. R., et al.: 3-year update from the Epcore NHL-1 trial: epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. *Blood*, 2024, 144, suppl. 1, s. 4480.
- 31 Dickinson, M. J. – Carlo-Stella, C. – Morschhauser, F., et al.: Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*, 2022, 387, s. 2220–2231.
- 32 Kim, J. – Cho, J. – Lee, M. H., et al.: CART cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. *Blood*, 2024, 144, s. 629–638.
- 33 Topp, M. S. – Tani, M. – Dickinson, M., et al.: Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a 12-month analysis from a phase Ib study. *Blood*, 2023, 142, suppl. 1, s. 3085.
- 34 Barba, P. – Kwon, M. – Briones, J., et al.: YTB323 (rapcabtagene autoleucel) demonstrates durable efficacy and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma: phase I study update. *Blood*, 2022, 140, suppl. 1, s. 1056–1059.
- 35 Shah, N. N. – Maziarz, R. T. – Jacobson, C. A., et al.: Interim analysis of a phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T-cell therapy: zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA NCT04792489). *Transplant Cell Ther*, abstrakty z 2023 Tandem Meetings of ASTCT and CIBMT, 15.–19. 2. 2023, Orlando, Florida, USA, s. S13–S14
- 36 Ardeshtna, K. M. – Marzolini, M. A. V. – Norman, J., et al.: Phase 1/2 study of AUTO3 the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 followed by an anti-PD1 in patients with relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL): results of cohort 1 and 2 of the Alexander Study. *Blood*, 2019, 134, suppl. 1, s. 246.
- 37 Thomas, S. – Abken, H.: CART cell therapy becomes CHIC: "cytotoxicine help intensified CAR" T cells. *Front Immunol*, 2023, 13, 1090959.
- 38 Grover, N. S. – Beaven, A. W.: T-cell lymphoma: the CAR-T revolution is coming. *Blood*, 2024, 143, s. 1201–1202.
- 39 Hill, L. C. – Rouse, R. H. – Wu, M. J., et al.: Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas [published correction appears in *Blood*, 2024, 144, s. 1349]. *Blood*, 2024, 143, s. 1231–1241.
- 40 Jacobson, C. A. – Locke, F. L. – Ma, L., et al.: Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. *Transplant Cell Ther*, 2022, 28, s. 581.e1–581.e8.
- 41 Kuhn, A. – Roddie, C. – Kirkwood, A. A., et al.: A national service for delivering CD19 CAR-T in large B-cell lymphoma – The UK real-world experience. *Br J Haematol*, 2022, 198, s. 492–502.

Monoklonální protilátky – daratumumab, isatuximab, elotuzumab – v léčbě mnohočetného myelomu. Můžeme už myelom vyléčit?

prof. MUDr. Ivan Špička, CSc. I. interní klinika, klinika hematologické, LF UK a VFN, Praha

- 1 Kumar, S. K. – Dispenzieri, A. – Lacy, M. Q., et al.: Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. *Leukemia*, 2014, 28, s. 1122–1128.
- 2 Ocio, E. M. – Perrot, A. – Bories, P., et al.: Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. *Leukemia*, 2023, 37, s. 1521–1529.
- 3 Špička, I.: Imunologická léčba myelomu – bispecifické protilátky v roce 2023. *Acta Medicinæ*, 2024, 13, s. 58–59.
- 4 Moreau, P. – Attal, M. – Hulin, C., et al.: Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*, 2019, 394, s. 29–38.
- 5 Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators; Moreau, P. – Hulin, C. – Perrot, A., et al.: Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. *Lancet Oncol*, 2024, 25, s. 1003–1014.
- 6 Voorhees, P. M. – Kaufman, J. L. – Laubach, J., et al.: Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood*, 2020, 136, s. 936–945.
- 7 Voorhees, P. M. – Sborov, D. W. – Laubach, J., et al.: Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. *Lancet Haematol*, 2023, 10, s. e825–e837.
- 8 Chari, A. – Kaufman, J. L. – Laubach, J., et al.: Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. *Blood Cancer J*, 2024, 14, s. 107.
- 9 Menon, T. – Kataria, S. – Adhikari, R., et al.: Efficacy of daratumumab-based regimens compared to standard of care in transplant-eligible multiple myeloma: a meta-analysis. *Cureus*, 2021, 13, s. e15098.
- 10 Sonneveld, P. – Dimopoulos, M. A. – Boccadoro, M., et al.: PERSEUS trial investigators: Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*, 2024, 390, s. 301–313.
- 11 Špička, I.: Léčba mnohočetného myelomu – současné možnosti. *Acta Medicinæ*, 2017, 6, s. 56–62.
- 12 Facon, T. – Dimopoulos, M. A. – Leleu, X. P., et al.: IMROZ study group. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*, 2024, 391, 15971609.
- 13 Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators; Moreau, P. – Hulin, C. – Perrot, A., et al.: Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. *Lancet Oncol*, 2024, 25, s. 1003–1014.
- 14 Hasan, A. H. – Abid, M. A. – Tariq, B.: Isatuximab for stem cell transplant-ineligible multiple myeloma: an editorial. *Cureus*, 2024, 16, s. e72177.
- 15 Costa, B. A. – Costa, T. A. – Chagas, G. C. L., et al.: Addition of elotuzumab to backbone treatment regimens for multiple myeloma: an updated meta-analysis of randomized clinical trials. *Clin Lymphoma Myeloma Leuk*, 2025, 25, s. 32–44.
- 16 Nishimura, K. K. – Barlogie, B. – van Rhee, F., et al.: Long-term outcomes after autologous stem cell transplantation for multiple myeloma. *Blood Adv*, 2020, 4, s. 422–431.
- 17 Barlogie, B. – Mitchell, A. – van Rhee, F., et al.: Curing myeloma at last: defining criteria and providing the evidence. *Blood*, 2014, 124, s. 3043–3051.
- 18 Engelhardt, M. – Kortüm, K. M. – Goldschmidt, H., et al.: Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. *Haematologica*, 2024, 109, s. 2420–2435.

Biologická léčba systémové AL amyloidózy

MUDr. Tomáš Píka, Ph.D. Hematoonkologická klinika, LF UP a FN Olomouc

- 1 Kyle, R. A. – Gertz, M. A.: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. *Semin Hematol*, 1995, 32, s. 45–59.
- 2 Falk, R. H. – Comenzo, R. L. – Skinner, M.: The systemic amyloidosis. *New Engl J Med*, 1997, 337, s. 898–909.
- 3 Sipe, J. D. – Benson, M. D. – Buxbaum, J. N., et al.: Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. *Amyloid*, 2016, 23, s. 209–213.
- 4 Benson, M. D., et al.: Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. *Amyloid*, 2020, 27, s. 217–222.
- 5 Merlini, G.: AL amyloidosis: diagnosis and prognosis. *Haematologica*, 2007, 92, suppl. 2, s. 58–59.
- 6 Píka, T. – Hájek, R. – Flodr, P., et al.: Diagnostika a léčba systémové AL amyloidózy. Doporučení vypracovaná Českou myelomovou skupinou (CMG), Myelomovou sekci České hematologické společnosti ČLS JEP. *Transfúze Hematologie Dnes*, 2022, suppl. 1, s. 6–40.
- 7 Gertz, M. A. – Merlini, G.: Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. *Amyloid*, 2010, 17, s. 48–49.
- 8 Dispenzieri, A.: Assessing response and prognosis in AL amyloidosis. In: Gertz, M. A. – Rajkumar, S. V.: *Amyloidosis: diagnosis and treatment*. Springer Science, New York, 2010, s. 77–93.
- 9 Palladini, G. – Campana, C. – Klersy, C., et al.: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. *Circulation*, 2003, 107, s. 2440–2445.
- 10 Dispenzieri, A. – Gertz, M. A. – Kyle, R. A., et al.: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. *J Clin Oncol*, 2004, 22, s. 3751–3757.
- 11 Wechalekar, A. D. – Schonland, S. O. – Kastritis, E., et al.: A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood*, 2013, 121, s. 3420–3427.
- 12 Bochtler, T. – Hegenbart, U. – Kunz, Ch., et al.: Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. *J Clin Oncol*, 2015, 33, s. 1371–1378.
- 13 Palladini, G. – Dispenzieri, A. – Gertz, M. A., et al.: New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *J Clin Oncol*, 2012, 30, s. 4514–4549.
- 14 Dispenzieri, A. – Buadi, F. – Kumar, S. K., et al.: Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (MSMART) consensus statement. *Mayo Clin Proc*, 2015, 90, s. 1054–1081.
- 15 Muchtart, E., et al.: Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (MSMART) consensus statement 2020 update. *Mayo Clin Proc*, 2021, 96, s. 1390–1392.
- 16 Kastritis, E. – Palladini, G. – Minnema, M. C., et al.: Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. *N Engl J Med*, 2021, 385, s. 46–58.
- 17 Sancharawala, V. – Sarosiek, S. – Schulman, A., et al.: Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. *Blood*, 2020, 135, s. 1541–1547.
- 18 Roussel, M. – Merlini, G. – Chevret, S., et al.: A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. *Blood*, 2020, 135, s. 1531–1540.
- 19 Kimmich, C. R. – Terzer, T. – Benner, A., et al.: Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. *Blood*, 2020, 135, s. 1517–1530.
- 20 Sancharawala, V. – Wright, D. – Rosenzweig, M., et al.: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. *Blood*, 2007, 109, s. 492–496.
- 21 Palladini, G. – Russo, P. – Foli, A., et al.: Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. *Ann Hematol*, 2012, 91, s. 89–92.
- 22 Dispenzieri, A. – Lacy, M. – Zeldenrust, S., et al.: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. *Blood*, 2007, 109, s. 465–470.
- 23 Sancharawala, V. – Shelton, A. C. – Lo, S., et al.: Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. *Blood*, 2016, 128, s. 1059–1062.
- 24 Kastritis, E. – Anagnostopoulos, A. – Roussou, M., et al.: Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. *Haematologica*, 2007, 92, s. 1351–1358.
- 25 Kastritis, E. – Wechalekar, E. – Dimopoulos, M., et al.: Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. *J Clin Oncol*, 2010, 28, s. 1031–1037.

- 26 Palladini, G. – Sachchithanatham, S. – Milani, P., et al.: A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood*, 2015, 126, s. 612–615.
- 27 Kastritis, E., et al.: Bortezomib, melphalan, and dexamethasone for light chain amyloidosis. *J Clin Oncol*, 2020, 38, s. 3252–3260.
- 28 Muchtar, E. – Gertz, M. A. – Laplant, B., et al.: Phase 2 trial of ixazomib, cyclophosphamide and dexamethasone for treatment of previously untreated light chain amyloidosis. *Blood*, 2020, 136, s. 52–53.
- 29 Cohen, A. D. – Sharpley, F. – Gillmore, J. D., et al.: Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. *Br J Haematol*, 2020, 189, s. 643–649.
- 30 Premkumar, V. J. – Lentzsch, S. – Pan, S., et al.: Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. *Blood Cancer J*, 2021, 11, s. 10.
- 31 Pasquer, H. – Belhadj, K. – Dupuis, J., et al.: Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis. *Brit J Haematol*, 2021, 193, s. 674–677.
- 32 Khouri, J. – Anwer, F. – Samaras, C. J., et al.: Safety, tolerability and efficacy of Cael-101 in AL amyloidosis patients treated on a phase 2, open-label, dose selection study to evaluate the safety and tolerability of Cael-101 in patients with AL amyloidosis. *Blood*, 2020, 136, s. 21.
- 33 Emdin, M. – Morfino, P. – Crosta, L., et al.: Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. *Eur Heart J*, 2023, 25, s. B79–B84.
- 34 Sarubbi, C. – Abowali, H. – Varga, C., et al.: Treatment of AL amyloidosis in the era of novel and cellular therapies. *Front Oncol*, 2024, 14, 1425521.
- 35 Chakraborty, R. – Bhutani, D. – Maurer, M. S., et al.: Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. *Blood Cancer J*, 2023, 13, s. 1–4.
- 36 Forgeard, N. – Elessa, D. – Carpintero, A., et al.: Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. *Blood*, 2024, 143, s. 734–737.
- 37 Khwaja, J. – Bomsztyk, J. – Atta, M., et al.: Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. *Br J Haematol*, 2024, 204, s. 1811–1815.
- 38 Kastritis, E. – Palladini, G. – Dimopoulos, M. A., et al.: Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: A phase 2 study by the European myeloma network. *Blood*, 2022, 140, s. 7294–7296.

Biologická léčba astmatu – současné možnosti

MUDr. Eva Voláková, Ph.D. Klinika plicních nemocí a tuberkulózy, FN Olomouc a LF UP v Olomouci

- 1 World Health Organization (WHO). www.who.int.
- 2 GINA. Global strategy for Asthma Management and Prevention (2024 update). www.ginasthma.org.
- 3 Teřil, M. – Sedlák, V. – Krčmová, I.: *Doporučený postup diagnostiky a léčby těžkého astmatu*. Geum, 2023.
- 4 Howell, I. – Howell, A. – Pavord, I. D.: Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight. *J Exp Med*, 2023, 220, e20221212.
- 5 Ceny a úhrady léčiv. SÚKL. www.sukl.gov.cz.
- 6 Portacci, A. – Dragonieri, S. – Carpagnano, G. E.: Type-2 severe asthma comorbidities in the era of biologics: time to rethink clinical response? *Expert Rev Respir Med*, 2024, 18, s. 249–253.
- 7 Colombo, G. L. – Di Matteo, S. – Martinotti, C., et al.: Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. *Ther Adv Respir Dis*, 2019, doi: 10.1177/1753466619841350.
- 8 Agache, I. – Beltran, J. – Akdis, C., et al.: Efficacy and safety of treatment with biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologics in severe asthma. *Allergy*, 2020, 75, s. 1023–1042.
- 9 Ghanei, M. – Ghalebagh, B. – Sami, R., et al.: Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalence clinical trial. *Front Immunol*, 2024, 15, 1425906.
- 10 Helbig, G. – Czachor, K.: Clinical management of persistent hyper-eosinophilia. *Eur J Haematol*, 2025, doi: 10.1111/ejh.14396.
- 11 Hellmich, B. – Sanchez-Alamo, B. – Schirmer, J. H., et al.: EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. *Ann Rheum Dis*, 2024, 83, s. 30–47.
- 12 Pelaia, C. – Calabrese, C. – Vatrella, A., et al.: Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. *Biomed Res Int*, 2018, 2018, 4839230.
- 13 Caminati, M. – Micheletto, C. – Norelli, F., et al.: Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence. *Expert Opin Biol Ther*, 2024, 24, s. 15–23.
- 14 Bhatt, S. P. – Rabe, K. F. – Hanania, N. A.: NOTUS study investigators: Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. *N Engl J Med*, 2024, 390, s. 2274–2283.
- 15 Diver, S. – Khalifaoui, L. – Emson, C., et al.: CASCADE study investigators: Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med*, 2021, 9, s. 1299–1312.
- 16 Menzies-Gow, A. – Colice, G. – Griffiths, J. M., et al.: NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. *Respir Res*, 2020, 21, s. 266.
- 17 Corren, J. – Menzies-Gow, A. – Chupp, G., et al.: Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. *Am J Respir Crit Care Med*, 2023, 208, s. 13–24.
- 18 Jackson, D. J. – Wechsler, M. E. – Jackson, D. J.: SWIFT-1 and SWIFT-2 investigators; SWIFT-1 investigators; SWIFT-2 investigators: Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. *N Engl J Med*, 2024, 391, s. 2337–2349.
- 19 Deitersen, A. – Bontinck, L. – Conicx, G., et al.: A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY compound, in healthy volunteers. *Clin Transl Sci*, 2024, 17, s. e13864.
- 20 Calderon, A. A. – Dimond, S. – Choy, D. F., et al.: Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD. *Eur Respir Rev*, 2023, 32, 220144.

Novinky v léčbě autozomálně dominantních polycystických ledvin

doc. MUDr. Jana Reiterová, Ph.D. Klinika nefrologie, 1. LF UK a VFN, Praha

- 1 Bahlmann-Kroll, E. – Häckl, S. – Kramer, S., et al.: Empagliflozin in patients with autosomal dominant polycystic kidney disease (EM-PA-PKD): study protocol for a randomised controlled trial. *BMJ Open*, 2024, 14, s. e088317.
- 2 Blazer-Yost, B. L. – Bacallao, R. L. – Erickson, B. J., et al.: A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease. *Clin Kidney J*, 2021, 14, s. 1738–1746.
- 3 Chebib, F. T. – Nowak, K. L. – Chonchol, M. B., et al.: Polycystic kidney disease diet: what is known and what is safe. *Clin J Am Soc Nephrol*, 2024, 19, s. 664–682.
- 4 Lee, E. C. – Valencia, T. – Allerson, C., et al.: Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. *Nat Commun*, 2019, 10, s. 4148.
- 5 Leuenroth, S. J. – Bencivenga, N. – Igarashi, P., et al.: Triptolide reduces cystogenesis in a model of ADPKD. *J Am Soc Nephrol*, 2008, 19, s. 1659–1662.
- 6 Perrone, R. D. – Abebe, K. Z. – Watnick, T. J., et al.: Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). *Kidney Int*, 2021, 100, s. 684–696.
- 7 Torres, V. E. – Chapman, A. B. – Devuyst, O., et al.: TEMPO 3:4 trial investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med*, 2012, 367, s. 2407–2418.
- 8 Torres, V. E. – Abebe, K. Z. – Chapman, A. B., et al.: HALT-PKD trial investigators: Angiotensin blockade in late autosomal dominant polycystic kidney disease. *N Engl J Med*, 2014, 371, s. 2267–2276.
- 9 van Aerts, R. M. M. – Kievit, W. – D’Agnolo, H. M. A., et al.: DPAK-1 investigators: Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease. *Gastroenterology*, 2019, 157, s. 481–491.
- 10 Tesař, V. – Ciechanowski, K. – Pei, Y., et al.: Bosutinib vs. placebo for autosomal dominant polycystic kidney disease. *J Am Soc Nephrol*, 2017, 28, s. 3404–3413.

Monoklonální protilátky v léčbě Alzheimerovy choroby

MUDr. Mgr. Adam Tesař, Ph.D. Neurologická klinika, 1. LF UK a VFN, Praha

- 1 Clifford, R. J. Jr. – Therneau, T. M. – Weigand, S. D., et al.: Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging-Alzheimer’s Association Research Framework. *JAMA Neurol*, 2019, 76, s. 1174–1183.
- 2 Nichols, E., et al.: Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet*, 2022, 7, s. e105–e125.
- 3 Georges, J. – Miller, O. – Bintener, Ch.: Estimating the prevalence of dementia in Europe. 2020. DOI:10.13140/RG.2.2.16880.81923.
- 4 Kim, C. K. – Lee, Y. R. – Ong, L., et al.: Alzheimer’s disease: key insights from two decades of clinical trial failures. *J Alzheimers Dis*, 2022, 87, s. 83–100.
- 5 Goedert, M.: Oskar Fischer and the study of dementia. *Brain*, 2009, 132, s. 1102–1111.
- 6 Trejo-Lopez, J. A. – Yachnis, A. T. – Prokop, S.: Neuropathology of Alzheimer’s disease. *Neurotherapeutics*, 2022, 19, s. 173–185.
- 7 Kepp, K. P. – Robakis, N. K. – Høiland-Carlson, P. F., et al.: The amyloid cascade hypothesis: an updated critical review. *Brain*, 2023, 146, s. 3969–3990.
- 8 Ellis, C. – Ward, N. L. – Rice, M., et al.: The structure of an amyloid precursor protein/talin complex indicates a mechanical basis of Alzheimer’s disease. *Open biology*, 2024, doi.org/10.1098/rsob.240185.
- 9 Salahuddin, P. – Fatima, M. T. – Abdelhameed, A. S., et al.: Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches. *Eur J Med Chem*, 2016, 114, s. 41–58.
- 10 Sperling, R. – Mormino, E. – Johnson, K.: The evolution of preclinical Alzheimer’s disease: implications for prevention trials. *Neuron*, 2014, 84, s. 608–622.
- 11 van der Kant, R., et al.: Amyloid-β-independent regulators of tau pathology in Alzheimer disease. *Nat Rev Neurosci*, 2020, 21, s. 21–35.
- 12 Samudra, N. – Lane-Donovan, C. – Vande Vrede, L., et al.: Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. *J Clin Invest*, 2023, 133, s. e168553.
- 13 Weigand, A. J. – Bangen, K. J. – Thomas, K. R., et al.: Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity. *Brain Commun*, 2020, 2, s. fcz046.
- 14 Arnsten, A. F. – Datta, D. – Del Tedici, K., et al.: Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease. *Alzheimers Dement*, 2021, 17, s. 115–124.
- 15 Zhang, J. – Zhang, Y. – Wang, J., et al.: Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. *Sig Transduct Target Ther*, 2024, 9, 211, doi.org/10.1038/s41392-024-01911-3.
- 16 Selvackadunco, S. – Langford, K. – Shah, Z., et al.: Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. *J Neural Transm*, 2019, 126, s. 327–337.
- 17 Olfati, N. – Shoeibi, A. – Litvan, I.: Clinical spectrum of Tauopathies. *Front Neurol*, 2022, 13, 944806.
- 18 Matej, R. – Tesař, A. – Rusina, R.: Alzheimer’s disease and other neurodegenerative dementias in comorbidity: a clinical and neuropathological overview. *Clin Biochem*, 2019, 73, s. 26–31.
- 19 Hansson, O. – Lehmann, S. – Otto, M., et al.: Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s disease. *Alzheimers Res Ther*, 2019, 11, s. 34.
- 20 Ossenkoppele, R. – Rabinovici, G. D. – Smith, R., et al.: Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. *JAMA*, 2018, 320, s. 1151–1162.

- 21 Anoop, A. – Singh, P. K. – Jacob, R. S., et al.: CSF biomarkers for Alzheimer's disease diagnosis. *Int J Alzheimers Dis*, 2010, 2010, 606802.
- 22 Pais, M. V. – Forlenza, O. V. – Diniz, B. S.: Plasma biomarkers of Alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice. *J Alzheimers Dis Rep*, 2023, 7, s. 355–380.
- 23 Szabo, P. – Mujalli, D. M. – Rotondi, M. L., et al.: Measurement of anti-beta amyloid antibodies in human blood. *J Neuroimmunol*, 2010, 227, s. 167–174.
- 24 Winblad, B. – Graf, A. – Riviere, M. E., et al.: Active immunotherapy options for Alzheimer's disease. *Alz Res Therapy*, 2014, 6, s. 7
- 25 Nicoll, J. A. – Buckland, G. R. – Harrison, C. H., et al.: Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. *Brain*, 2019, 142, s. 2113–2126.
- 26 Mantile, F. – Prisco, A.: Vaccination against β -amyloid as a strategy for the prevention of Alzheimer's disease. *Biology*, 2020, 9, s. 425.
- 27 Kim, C. K. – Lee, Y. R. – Ong, L., et al.: Alzheimer's disease: key insights from two decades of clinical trial failures. *J Alzheimers Dis*, 2022, 87, s. 83–100.
- 28 Lansdall, C. J. – McDougall, F. – Butler, L. M., et al.: Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease. *J Prev Alzheimers Dis*, 2023, 10, s. 9–18.
- 29 Heneka, M. T. – Morgan, D. – Jessen, F.: Passive anti-amyloid β immunotherapy in Alzheimer's disease-opportunities and challenges. *Lancet*, 2024, s. 2198–2208.
- 30 Salloway, S. – Chalkias, S. – Barkhof, F., et al.: Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. *JAMA Neurol*, 2022, 79, s. 13–21.
- 31 Hampel, H. – Elhage, A. – Cho, M., et al.: Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. *Brain*, 2023, 146, s. 4414–4424.
- 32 Sims, J. R. – Zimmer, J. A. – Evans, C. D., et al.: Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*, 2023, 330, s. 512–527.
- 33 Greenberg, S. M. – Aparicio, H. J. – Furie, K. L., et al.: Vascular neurology considerations for anti-amyloid immunotherapy: a science advisory from the American Heart Association. *Stroke*, 2024, doi/10.1161/STR.000000000000480.
- 34 How to get Mounjaro (Tirzepatide) in 2025, and what to know. Dostupné z: <https://investor.lilly.com/node/51501/pdf>, vyhledáno 16. 1. 2025.
- 35 Cullen, N. C. – Novak, P. – Tosun, D., et al.: Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. *EBioMedicine*, 2024, 99, 104923.
- 36 Del Giudice, K. P. – Cosgaya, M. – Zaro, I., et al.: Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work? *Parinsonism Relat Disord*, 2024, 122, 106080.

Lupusová nefritida – co nám přináší nová doporučení?

MUDr. Ester Kurašová | prof. MUDr. Karel Krejčí, Ph.D. | prof. MUDr. Pavel Horák, CSc. Univerzita Palackého v Olomouci, Lékařská fakulta a Fakultní nemocnice Olomouc, III. interní klinika – nefrologická, revmatologická a endokrinologická

- 1 KDIGO 2024 clinical practice guideline for the management of lupus nephritis. *Kidney International*, 2024, 105, suppl. 15, s. S1–S69. Dostupné z: <https://kdigo.org/wp-content/uploads/2024/01/KDIGO-2024-Lupus-Nephritis-Guideline.pdf>, vyhledáno 10. 1. 2024.
- 2 Mok, C. C. – Teng, Y. K. O. – Saxena, R., et al.: Treatment of lupus nephritis: consensus, evidence and perspectives. *Nat Rev Rheumatol*, 2023, 19, s. 227–238.
- 3 Deshmukh, U. S. – Gaskin, F. – Lewis, J. E., et al.: Mechanisms of autoantibody diversification to SLE-related autoantigens. *Ann NY Acad Sci*, 2003, 987, s. 91–98.
- 4 Matl, I.: Léčba lupusové nefritidy. *Interní Med Praxi*, 2012, 14, s. 206–208.
- 5 Fanouriakis, A. – Kostopoulou, M. – Andersen, J., et al.: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis*, 2024, 83, s. 15–29.
- 6 Anders, H. J. – Furie, R. – Malvar, A., et al.: Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. *Nephrol Dial Transplant*, 2023, 38, s. 2733–2742.
- 7 Parodis, I. – Lindblom, J. – Cetzrez, N., et al.: Effect of belimumab on preventing de novo renal lupus flares. *Kidney Int Rep*, 2023, 8, s. 1822–1830.
- 8 Rovin, B. H. – Teng, Y. K. O. – Ginzler, E. M., et al.: Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*, 2021, 397, s. 2070–2080.
- 9 Saxena, A. – Ginzler, E. M. – Gibson, K., et al.: Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. *Arthritis Rheumatol*, 2024, 76, s. 59–67.
- 10 Steiger, S. – Anders, H. J.: Interferon blockade in Lupus: effects on antiviral immunity. *Nat Rev Nephrol*, 2022, 18, s. 415–416.
- 11 Jayne, D. – Mysler, E. – Amoura, Z., et al.: Identification of urine metabolites linked to disease activity that are modulated by anifrolumab in a phase 2 LN trial using untargeted metabolomics analysis [abstract]. *Arthritis Rheumatol*, 2023, 75, suppl. 9.
- 12 Tan, B. – So, P. N. – Krishnan, A., et al.: GlomCon Editorial Team: Approach to pregnancy in patients with lupus nephritis. *Kidney Med*, 2023, 5, 100724.
- 13 Rovin, B. H., et al.: KDIGO 2024 lupus nephritis guidelines visual abstract. *Kidney International*, 2024, 105, suppl. 15, s. S1–S69.
- 14 Pattanaik, D. – Green, J. – Talwar, M., et al.: Relapse and outcome of lupus nephritis after renal transplantation in the modern immunosuppressive era. *Cureus*, 2022, 14(1):e20863.

Biosimilární léčiva v dermatologii u pacientů s diagnózou psoriasis vulgaris, efektivita a cenové přínosy – kazuistika

MUDr. et Bc. Lucie Jarešová DermaMedEst, s. r. o.

- 1 Reis, C. D. – Teixo, R. – Mendes, F., et al.: Biosimilar medicines – Review. *Int J Risk Saf Med*, 2016, 28, s. 45–60.
- 2 Gulácsi, L. – Péntek, M. – Rencz, F., et al.: Biosimilars for the management of inflammatory bowel diseases: Economic considerations. *Curr Med Chem*, 2019, 26, s. 259–269.
- 3 Sagaría, N. – Mengato, D. – Corbucci, I., et al.: IISG-002 Biological drugs for the treatment of moderate and severe plaque psoriasis: a cost analysis and an application of a correlation analysis to investigate cost effectiveness. *Europ J Hospit Pharm*, 2020, 27, s. A1.
- 4 Hasanolkoli, D. – Miraçi, M. – Backa, T., et al.: Biologics and biosimilars in Albania; consumption and costs. *International Journal on Bioinformatics & Biosciences*, 2024, 14, s. 1–9.
- 5 Kurki, P.: Comparative efficacy studies of biosimilars: data versus theoretical risks, beliefs, and comfort. *GaBI*, 2024, 13, s. 23–26.
- 6 Simoens, S.: Biosimilar medicines and cost-effectiveness. *Clinicoecon Outcomes Res*, 2011, 3, s. 29–36.
- 7 Gizzo, S. – Ferrando, M. – Lispi, M., et al.: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. *J Med Econ*, 2018, 21, s. 1096–1101.
- 8 Hussein, R. S. – Dayal, S.: Biosimilars in dermatology: A promising solution to the high cost of biologic therapy. *Intern J Life Scien Pharma Res*, 2023, 13, s. 110–115.

Behçetova nemoc

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

prof. MUDr. Jarmila Heissigerová, Ph.D., MBA Oční klinika, 1. LF UK a VFN, Praha

- 1 Maldini, C., et al.: Exploring the variability of Behçet's disease prevalence: meta-analytical approach. *Rheumatology*, 2018, 57, s. 185–195.
- 2 Gül, A., et al.: Familial aggregation of Behçet's disease in Turkey. *Ann Rheum Dis*, 2000, 59, s. 622–625.
- 3 Takeuchi, M., et al.: Dense genotyping of immune related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. *Nat Genet*, 2017, 49, s. 438–443.
- 4 Takeuchi, M., et al.: The immunogenetics of Behçet's disease: a comprehensive disease review. *J Autoimmun*, 2015, 64, s. 137–148.
- 5 Le Joncour, A., et al.: Critical role of neutrophil extracellular traps (NETs) in patients with Behçet's disease. *Ann Rheum Dis*, 2019, 78, s. 1274–1282.
- 6 Kirino, Y., et al.: Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet's disease: a retrospective observational study. *Arthritis Res Ther*, 2016, 18, s. 2178.
- 7 Gül, A.: Behçet's disease. In: Hochberg, M., et al.: *Rheumatology*. ClinicalKey, Elsevier, Philadelphia, 2023, s. 1467–1474. Dostupné z: <https://www.clinicalkey.com/#/content/book/3-s2.0-B9780702068652001676>, vyhledáno 4. 2. 2025.
- 8 Saip, S., et al.: Neuro-Behçet's syndrome. *Handb Clin Neurol*, 2014, 121, s. 1703–1723.
- 9 Hatemi, G., et al.: 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis*, 2018, 77, s. 808–818.
- 10 Hatemi, G.: Apremilast for Behçet's syndrome – a phase 2, placebo controlled trial. *N Engl J Med*, 2015, 372, s. 1510–1518.
- 11 Melikoglu, M., et al.: Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. *J Rheumatol*, 2005, s. 3298–3105.
- 12 Bettiol, A., et al.: The right place of interleukin 1 inhibitors in the treatment of Behçet's syndrome: a systematic review. *Rheumatology Inter*, 2019, 35, s. 971–990.
- 13 Vallet, H., et al.: Efficacy of anti-TNF alfa in severe and/or refractory Behçet's disease. Multicenter study of 124 patients. *J Autoimmun*, 2015, 62, s. 667–674.
- 14 Belén, A. M.: Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease: National Multicenter Study of 177 cases. *Arthritis Rheumatology*, 2019, 71, s. 2081–2089.
- 15 Zeydan, B., et al.: Infliximab is plausible alternative for neurologic complications of Behçet's disease. *Neurol Neuroimmunol Neuroinflamm*, 2016, 3, s. e258.
- 16 Hatemi, I., et al.: Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behçet's syndrome. A stroke-compliant observational study from a dedicated multidisciplinary center. *Medicine*, 2016, 95, s. e3348.
- 17 Naganuma, M., et al.: Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. *Inflamm Bowel Dis*, 2008, 14, s. 1259–1264.

Mirikizumab v terapii Crohnovy choroby

doc. MUDr. Martin Bortlík, Ph.D. Gastroenterologické oddělení, Nemocnice České Budějovice, a. s.; Interní klinika, 1. LF UK a ÚVN, Praha; Farmakologický ústav, 1. LF UK, Praha; Zdravotně sociální fakulta Jihočeské univerzity, České Budějovice

- 1 SPC Omvoh, dostupné z: https://www.ema.europa.eu/cs/documents/product-information/omvoh-epar-product-information_cs.pdf, vyhledáno 12. 3. 2025.
- 2 Steere, B. – Schmitz, J. – Powell, N., et al.: Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study. *Clin Transl Gastroenterol*, 2023, 14, e00578.
- 3 Johnson, T. – Steere, B. – Zhang, P., et al.: Mirikizumab-induced transcriptome changes in ulcerative colitis patient biopsies at week 12 are maintained through week 52. *Clin Transl Gastroenterol*, 2023, 14, e00630.
- 4 Sands, B. E. – Peyrin-Biroulet, L. – Kierkus, J., et al.: Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease. *Gastroenterology*, 2022, 162, s. 495–508.
- 5 Ferrante, M. – D'Haens, G. – Jairath, V., et al.: Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. *Lancet*, 2024, 404, s. 2423–2436.
- 6 Peyrin-Biroulet, L. – Chapman, J. C. – Colombel, J. F., et al.: Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease. *N Engl J Med*, 2024, 391, s. 213–223.

Stilova choroba dospělých – kazuistika

MUDr. Ondřej Sglunda Poliklinika Modrý pavilon, Slezská Ostrava

- 1 Yamaguchi, M., et al.: Preliminary criteria for classification of adult Still's disease. *J Rheumatol*, 1992, 19, s. 424–430.
- 2 Bywaters, E. G.: Still's disease in the adult. *Ann Rheum Dis*, 1971, 30, s. 121–133.
- 3 Miossec, P., et al.: Interleukin-1 blockade in the treatment of autoinflammatory diseases. *Autoimmun Rev*, 2018, 17, s. 665–675.
- 4 EULAR recommendations for the management of adult-onset Still's disease. Dostupné z www.eular.org.
- 5 Fautrel, B., et al.: Adult-onset Still's disease. *Best Pract Res Clin Rheumatol*, 2012, 26, s. 477–487.
- 6 Harrison's Principles of Internal Medicine. 20. vydání, New York, McGraw-Hill Education, 2018. Kapitola o vzácných revmatických onemocněních.
- 7 UpToDate. Adult-onset Still's disease: Clinical manifestations, pathophysiology, and treatment. Dostupné z: www.uptodate.com.
- 8 Fautrel, B. – Mitrovic, S. – De Matteis, A., et al.: EULAR/PreS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. *Ann Rheum Dis*, 2024, 83, s. 1614–1627.

Psoriáza – přehled o terapii; indikace k biologické léčbě

doc. MUDr. Jarmila Čelakovská, Ph.D. Klinika nemocí kožních a pohlavních, FN a LF UK v Hradci Králové

- 1 Robinson, A. – Kardos, M. – Kimball, A. B.: Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. *J Am Acad Dermatol*, 2012, 66, s. 369–375.
- 2 Finlay, A. Y.: Patient-reported outcome measures in psoriasis: Assessing the assessments. *Br J Dermatol*, 2015, 172, s. 1178–1179.
- 3 Nast, A. – Gisondi, P. – Ormerod, A. D., et al.: European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015-Short vision-EDF in cooperation with EADV and IPC. *J Eur Acad Dermatol Venereol*, 2015, 29, s. 2277–2294.
- 4 Finlay, A. Y.: Current severe psoriasis and the rule of tens. *Br J Dermatol*, 2005, 152, s. 861–867.
- 5 Mrowietz, U. – Kragballe, K. – Reich, K., et al.: Definition of treatment goals for moderate to severe psoriasis: A European consensus. *Arch Dermatol Res*, 2011, 303, s. 1–10.
- 6 Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Psoriasis 2004. Dostupné z: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf, vyhledáno 30. 9. 2017.
- 7 Gisondi, P. – Altomare, G. – Ayala, F., et al.: Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. *J Eur Acad Dermatol Venereol*, 2017, 31, s. 774–790.
- 8 Daudén, E. – Puig, L. – Ferrándiz, C., et al.: Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. *J Eur Acad Dermatol Venereol*, 2016, 30, s. 1–18.
- 9 Piaserico, S. – Cazzaniga, S. – Chimenti, S., et al.: Efficacy of switching between tumor necrosis factor- α inhibitors in psoriasis: Results from the Italian Psocare registry. *J Am Acad Dermatol*, 2014, 70, doi: 10.1016/j.jaad.2013.10.019.
- 10 Saeki, H. – Imafuku, S. – Abe, M., et al.: Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients. *J Dermatol*, 2015, 42, s. 367–372.
- 11 Kuhn, A. – Ruland, V. – Patsinakidis, N., et al.: Use of methotrexate in patients with psoriasis. *Clin Exp Rheumatol*, 2010, 28, suppl. 61, s. S138–44.
- 12 Heath, M. S. – Sahni, D. R. – Curry, Z. A., et al.: Pharmacokinetics of tazarotene and acitretin in psoriasis. *Expert Opin Drug Metab Toxicol*, 2018, 14, s. 919–927.
- 13 Mozzanica, N. – Pigatto, P. D. – Finzi, A. F.: Cyclosporin in psoriasis: pathophysiology and experimental data. *Dermatology*, 1993, 187, suppl. 1, s. 3–7.
- 14 Bos, J. D. – Meinardi, M. M. – van Joost, T., et al.: Use of cyclosporin in psoriasis. *Lancet*, 1989, 2, s. 1500–1502.
- 15 Papp, K. – Gottlieb, A. B. – Naldi, L., et al.: Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). *J Drugs Dermatol*, 2015, 14, s. 706–714.
- 16 Gottlieb, A. B. – Kalb, R. E. – Langley, R. G., et al.: Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies. *J Drugs Dermatol*, 2014, 13, s. 1441–1448.
- 17 Reich, K. – Wozel, G. – Zheng, H., et al.: Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: Results of a randomized, long-term extension trial (RESTORE2). *Br J Dermatol*, 2013, 168, s. 1325–1334.
- 18 Naldi, L. – Addis, A. – Chimenti, S., et al.: Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. *Dermatology*, 2008, 217, s. 365–373.
- 19 Song, G. G. – Seo, Y. H. – Kim, J. H., et al.: Association between TNF- α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF- α blockers in spondyloarthritis, psoriasis and Crohn's disease: A meta-analysis. *Pharmacogenomics*, 2015, 16, s. 1427–1437.
- 20 Prieto-Pérez, R. – Solano-López, G. – Cabaleiro, T., et al.: The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis. *Pharmacogenomics*, 2015, 16, s. 1723–1731.
- 21 Talamonti, M. – Galluzzi, M. – van den Reek, J. M., et al.: Role of the HLA-C*06 allele in clinical response to ustekinumab: Evidence from real life in a large cohort of European patients. *Br J Dermatol*, 2017, 177, s. 489–496.
- 22 Saleem, M. B. – Feldman, S. R.: Comorbidities in patients with psoriasis: The role of the dermatologist. *J Am Acad Dermatol*, 2017, 77, s. 191–192.
- 23 Barrea, L. – Savanelli, M. C. – di Somma, C., et al.: Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. *Rev Endocr Metab Disord*, 2017, 18, s. 195–205.
- 24 Kinahan, C. E. – Mazloom, S. – Fernandez, A. P.: Impact of smoking on response to systemic treatment in patients with psoriasis: A retrospective case-control study. *Br J Dermatol*, 2015, 172, s. 428–436.
- 25 Jensen, P. – Christensen, R. – Zachariae, C., et al.: Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up study. *Am J Clin Nutr*, 2016, 104, s. 259–265.
- 26 Barrea, L. – Balato, N. – di Somma, C., et al.: Nutrition and psoriasis: Is there any association between the severity of the disease and adherence to the Mediterranean diet? *J Transl Med*, 2015, 13, s. 18.
- 27 Gisondi, P.: High prevalence of alcohol use disorders in patients with inflammatory skin diseases applies to both psoriasis and eczema. *Br J Dermatol*, 2017, 177, s. 606–607.
- 28 Schmitt, J. – Wozel, G. – Garzaroli, M., et al.: Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: A pragmatic randomised controlled trial. *Acta Derm-Venereol*, 2014, 94, s. 192–197.
- 29 Fernandez-Torres, R. M. – Parada, S. – Fonseca, E.: Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. *J Nutr Health Aging*, 2012, 16, s. 586–591.
- 30 Murase, J. E. – Heller, M. M. – Butler, D. C.: Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. *J Am Acad Dermatol*, 2014, 70, s. 401.
- 31 Nast, A. – Spuls, P. I. – van der Kraaij, G., et al.: European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC. *J Eur Acad Dermatol Venereol*, 2017, doi: 10.1111/jdv.14454.
- 32 Fabiano, A. – de Simone, C. – Gisondi, P., et al.: Management of patients with psoriasis treated with biological drugs needing a surgical treatment. *Drug De Res*, 2014, 75, s. S24–S26.
- 33 Bakkour, W. – Poursell, H. – Chinoy, H., et al.: The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. *J Eur Acad Dermatol Venereol*, 2016, 30, s. 86–91.
- 34 Hannen, R. – Udeh-Momoh, C. – Upton, J., et al.: Dysfunctional skin-derived glucocorticoid synthesis is a pathogenic mechanism of psoriasis. *J Invest Dermatol*, 2017, 137, s. 1630–1637.
- 35 Simopoulou, T. – Tsiogkas, S. G. – Zafriou, E., et al.: Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. *Drugs Today*, 2023, 59, s. 135–167.
- 36 Baeten, D. – Sieper, J. – Braun, J., et al.: MEASURE 1 study group; MEASURE 2 study group: Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. *N Engl J Med*, 2015, 373, s. 2534–2548.

Psoriáza a obezita: co bychom měli vědět? Kazuistika pacientky s těžkou formou psoriázy a obezitou, úspěšně léčené ixekizumabem

MUDr. Michaela Nováková Dermatovenerologická klinika, FN Bulovka a 2. LF UK; Dermatovenerologická ambulance, IKEM, Praha

- 1 Ruiz-Villaverde, R. – Ezomo-Gervilla, P. J. – Molina-Espinosa, J., et al.: Comparative analysis of ixekizumab effectiveness with and without induction therapy in moderate-to-severe psoriasis: a real-world study. *J Clin Med*, 2025, 14, s. 833.
- 2 Mustáň, M. L. – Ionescu, M. – Radu, L., et al.: The role of metabolic syndrome in psoriasis treatment response: a one-year comparative analysis of PASI progression. *Diagnostics*, 2024, 14, s. 2887.
- 3 Di Caprio, R. – Nigro, E. – Di Brizzi, E. V., et al.: Exploring the link between psoriasis and adipose tissue: one amplifies the other. *Int J Mol*

- Sci*, 2024, 25, s. 13435.
- 4 Haran, K. – Johnson, C. E. – Smith, P., et al.: Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review. *Psoriasis*, 2024, 14, s. 143–152.
 - 5 Lambadiari, V. – Katsimbri, P. – Kountouri, A., et al.: The effect of a ketogenic diet versus mediterranean diet on clinical and biochemical markers of inflammation in patients with obesity and psoriatic arthritis: a randomized crossover trial. *Int J Mol Sci*, 2024, 25, s. 2475.
 - 6 Scala, E. – Mercurio, L. – Albanesi, C., et al.: The intersection of the pathogenic processes underlying psoriasis and the comorbid condition of obesity. *Life*, 2024, 14, s. 733.
 - 7 Guo, L. – Kircik, L. – Armstrong, A. W.: Individual article: Psoriasis and obesity: optimizing pharmacologic treatment and lifestyle interventions. *J Drugs Dermatol*, 2025, 24, s. 491722s4–491722s14.
 - 8 Egeberg, A. – Merola, J. F. – Schäkel, K., et al.: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. *Front Med*, 2023, 9, 1092688.
 - 9 Sendrea, A.-M. – Cristea, S. – Salavastru, C. M.: Nutritional status in pediatric psoriasis: a case-control study in a tertiary care referral centre. *Children*, 2024, 11, s. 885.
 - 10 Reich K. – Puig, L. – Mallbris, L., et al.: The effect of body weight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. *J Eur Acad Dermatol Venereol*, 2017, 31, s. 1196–1207.
 - 11 Vilarrasa, E. – Nicolau, J. – de la Cueva, P., et al.: Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. *Actas Dermosifiliogr*, 2024, 115, s. 56–65.
 - 12 Cai, W. – Zhang, R. – Yao, Y., et al.: Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. *Front Public Health*, 2024, 12, 1277113.
 - 13 Dostupné z: https://www.ema.europa.eu/cs/documents/product-information/mounjaro-epar-product-information_cs.pdf, vyhledáno 17. 3. 2025.
 - 14 Wang, J. – Yu, Y. – Liu, L., et al.: Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades. *Autoimmun Rev*, 2024, 23, 103577.
 - 15 Vata, D. – Tarcau, B. M. – Popescu, I. A., et al.: Update on obesity in psoriasis patients. *Life*, 2023, 13, s. 1947.